Investor List:

Top Therapeutics Series B Investors in Los Angeles / Southern California (13)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Aiden Aceves, Vice President at Insight Partners
Aiden Aceves
Insight Partners·Vice President
Sweet spot: $25.0M
Range: $10.0M - $350.0M
Investors in San Diego (CA)
Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in Los Angeles / Southern California (Other Lists)
Photo of Jason Camm, Managing Director at Thiel Capital
Jason Camm
Thiel Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in West Hollywood (CA)
Photo of Fabian Hansen, Managing Director at Presight Capital
Fabian Hansen
Presight Capital·Managing Director
Sweet spot: $10.0M
Range: $500K - $20.0M
Investors in Los Angeles (CA)
Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Therapeutics (Seed), Investors in Consumer Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in FinTech (Seed), Investors in DeepTech (Seed), Investors in Consumer Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in FinTech (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Series A), Investors in Therapeutics (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in FinTech (Series A), Investors in DeepTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in FinTech (Series A), Investors in DeepTech (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in FinTech (Series B), Investors in DeepTech (Series B), Investors in Consumer Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in FinTech (Series B), Investors in Los Angeles / Southern California (Other Lists)
Photo of Blake Masters, Principal at Thiel Capital
Blake Masters
Thiel Capital·Principal
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in San Francisco (CA), Investors in Tucson (AZ), Investors in Los Angeles (CA)
Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Manufacturing (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in Manufacturing (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Paul Deneys, Vice President at Thiel Capital
Paul Deneys
Thiel Capital·Vice President
Sweet spot: $1.5M
Range: $100K - $1.5M
Investors in West Hollywood (CA)
Photo of Justin Dyer, Partner at AWM Capital
Justin Dyer
AWM Capital·Partner
Sweet spot: $500K
Range: $100K - $2.0M
Investors in Los Angeles (CA)
Investors in Parenting/Families (Seed), Investors in Therapeutics (Seed), Investors in Cybersecurity (Seed), Investors in Wellness & Fitness (Seed), Investors in Insurance (Seed), Investors in Enterprise Applications (Seed), Investors in Logistics (Seed), Investors in Parenting/Families (Seed), Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in FinTech (Seed), Investors in Logistics (Seed), Investors in Cybersecurity (Seed), Investors in Enterprise Applications (Seed), Investors in Insurance (Seed), Investors in FinTech (Seed), Investors in Parenting/Families (Series A), Investors in Therapeutics (Series A), Investors in Cybersecurity (Series A), Investors in Insurance (Series A), Investors in Wellness & Fitness (Series A), Investors in Logistics (Series A), Investors in Parenting/Families (Series A), Investors in Enterprise Applications (Series A), Investors in Therapeutics (Series A), Investors in FinTech (Series A), Investors in Wellness & Fitness (Series A), Investors in Logistics (Series A), Investors in Cybersecurity (Series A), Investors in Insurance (Series A), Investors in Enterprise Applications (Series A), Investors in FinTech (Series A), Investors in Parenting/Families (Series B), Investors in Cybersecurity (Series B), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Insurance (Series B), Investors in Parenting/Families (Series B), Investors in Logistics (Series B), Investors in Enterprise Applications (Series B), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in FinTech (Series B), Investors in Logistics (Series B), Investors in Cybersecurity (Series B), Investors in Insurance (Series B), Investors in Enterprise Applications (Series B), Investors in FinTech (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists)
Photo of Daniel Lennon, Venture Partner at Palo Santo VC
Daniel Lennon
Palo Santo VC·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Los Angeles (CA)
Get new data & insights delivered to your inbox